The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network.
Masyar Gardizi
No relevant relationships to disclose
Matthias Scheffler
No relevant relationships to disclose
Lukas Carl Heukamp
No relevant relationships to disclose
Marc Christiaan Allardt Bos
No relevant relationships to disclose
Kerstin Albus
No relevant relationships to disclose
Birgit Hayn
No relevant relationships to disclose
Yon-Dschun Ko
No relevant relationships to disclose
Andreas Schlesinger
No relevant relationships to disclose
Michael Brockmann
No relevant relationships to disclose
Monika Heidi Serke
No relevant relationships to disclose
Ulrich Gerigk
No relevant relationships to disclose
Khosro Hekmat
No relevant relationships to disclose
Erich Stoelben
No relevant relationships to disclose
Marcel Reiser
No relevant relationships to disclose
Roland Schnell
No relevant relationships to disclose
Stephan H. Schmitz
No relevant relationships to disclose
Konrad Frank
No relevant relationships to disclose
Reinhard Buettner
No relevant relationships to disclose
Jurgen Wolf
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca
Research Funding - Novartis
Thomas Zander
No relevant relationships to disclose